NCT04789928

Conservative Treatment of Catheter - Related Injections With Gentamicine/EDTA

Gentamicine-EDTA, a New Anti-biofilm Strategy for the Conservative Treatment of Catheter-related Infections

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Institut Pasteur · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Catheter-related infections are frequent. Treatment without catheter removal is difficult because of the presence of biofilm. The association of gentamicin and EDTA is active in vitro and in vivo against biofilms formed by Gram positive and Gram negative bacteria.

Conditions

• Patients With Uncomplicated Long-term Central Venous Catheter-related Biofilm-related Infection

Interventions

Type	Name	Description
DRUG	Gentamicins-EDTA	Patients included in this study will receive daily injection (up to 10 days) of genta-EDTA-Na2 lock associated with systemic antibiotics.

Timeline

• Start date: 2021-01-05
• Primary completion: 2023-12-31
• Completion: 2024-03-01
• First posted: 2021-03-10
• Last updated: 2024-06-05

Locations

6 sites across 1 country: France